Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF

Abstract

Cancer-related epidemiological data are alarming. In 2018, 18 million new cases were diagnosed worldwide, with 52% of these patients dying. In Brazil, the numbers are equally worrying, with 627,000 new diagnoses expected for the 2020-2022 triennium. The main systemic treatment is chemotherapy, capable of, in most cases, a progression of the disease, associated with effects associated with debilitating effects. In this scenario, immunotherapy has to define the promise and the revolutionary, by stimulating its own defense mechanisms in the containment of tumors. The Gc protein-derived macrophage activating factor (GcMAF) is thus evaluated and capable of inhibiting immunosuppression mediated by transformed cells. In the present study, we evaluated the modulatory effects of GcMAF in Drosophila melanogaster using the epithelial tumor test (ETT) to predict its anticarcinogenicity in an experimental model that has high genetic homology with mammals. GcMAF isolated in the configurations (25pg / ml, 50pg / ml and 100pg / ml), Vitamin D (VD-1mM), Doxorubicin (DOX-0.4mM) and as flats, GcMAF + VD, GcMAF + DOX, GcMAF + VD + DOX is also not a toxicity for D. melanogaster, these being the conditions evaluated in the ETT. Isolated GcMAF was not carcinogenic in any of the evaluated recommendations, nor when associated with VD. How to join GcMAF + DOX and GcMAF + DOX + VD dissipating modulatory effect on the carcinogenicity of DOX, with a reduction in the frequency of tumors when compared to the positive control (DOX - 0.4mM). Our study helps to understand the role of GcMAF in tumor control, allowing us to better characterize it as a cancer treatment strategy.